IIT Madras and Ohio State University researchers announced a new AI framework that dramatically reduces time, data complexity and cost required to discover new drug candidates. The system is designed to replace multiple slow manual pre-screen stages and compress pharmaceutical R&D cycles through predictive generative inference techniques, reducing dependency on expensive wet-lab experimental iteration. The breakthrough signals a structural shift where AI-led drug modeling could broaden affordable drug access, boosting innovation velocity for emerging markets, oncology research and rare disease programs that previously suffered from capital inefficiencies and slow preclinical validation funnels.